Sign in
Taking peoplePhase 3

Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractlity: an open label prospective randomized study

Key facts

Who runs it
Centre Hospitalier Universitaire Amiens Picardie
Where
France38 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
360 people, planned
Started
22 Oct 2024
Planned end
15 Jul 2025
Type of study
Interventional
Record updated
1 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Patient with a septic shock (according to the SEPSIS3 definition: sepsis with persisting hypotension (MAP<65mmHg or SAP <90mmHg) requiring vasopressors to maintain MAP>65mmHg with at least one lactate dosage >2 mmol/L during the current shock episode
  • patient who received between 10 and 30ml/kg of fluid and absence of fluid responsiveness
  • Left ventricular ejection fraction > 60 % (visual or Simpson method using echocardiography)
  • Tachycardia >95 bpm with a MAP 65mmHg for more than 1 hour
  • Patient either in spontaneous ventilation or intubated and ventilated

Who cannot take part

  • Patient treated with Dobutamine, adrenaline or isoprenaline
  • Patient currently treated with beta blockers (previous home betablocker treatment is not an exclusion criteria)
  • Hypersensitivity to the active substance or to any of the excipients
  • Decompensated heart failure when considered not related to the errhythmia
  • Presence of significant bleeding, or spontaneously ventilated patient in respiratory distress requiring immediate intubation
  • Patients with any form of cardiac pacing
  • Sick sinus syndrome
  • Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block
  • Known pulmonary hypertension
  • in- or out-of-hospital cardiac arrest without signs of early recovery
  • Patients with inclusion criteria already present for more than 36 hours
  • Non-treated phaeochromocytoma
  • Acute asthmatic attack
  • Severe bradycardia (less than 50 beats per minute)
  • Cardiogenic shock
  • Severe hypotension uncontrolled
  • Severe, uncorrectable metabolic acidosis
  • Moribund

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

is to demonstrate that the reduction of heart rate using the landiolol may improve the mortality of septic shock patients with tachycardia and hypercontractility in comparison to control group at day 28

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
1 October 2026